Inhibrx Biosciences Inc (NASDAQ: INBX)’s stock price has increased by 3.75% compared to its previous closing price of $15.74. However, the company has seen a 10.41% increase in its stock price over the last five trading sessions. prnewswire.com reported 2025-05-14 that SAN DIEGO, May 14, 2025 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the “Former Parent”) to Sanofi S.A.
Is It Worth Investing in Inhibrx Biosciences Inc (NASDAQ: INBX) Right Now?
Inhibrx Biosciences Inc (NASDAQ: INBX) has a price-to-earnings ratio of 0.14x that is above its average ratio. Additionally, the 36-month beta value for INBX is -0.14. There are mixed opinions on the stock, with 0 analysts rating it as a “buy”, 0 rating it as “overweight”, 2 rating it as “hold”, and 0 rating it as “sell”.
The public float for INBX is 9.87M and currently, short sellers hold a 7.93% ratio of that float. The average trading volume of INBX on July 04, 2025 was 104.30K shares.
INBX’s Market Performance
INBX’s stock has seen a 10.41% increase for the week, with a 20.69% rise in the past month and a 15.82% gain in the past quarter. The volatility ratio for the week is 5.54%, and the volatility levels for the past 30 days are at 5.85% for Inhibrx Biosciences Inc The simple moving average for the last 20 days is 11.10% for INBX stock, with a simple moving average of 15.97% for the last 200 days.
INBX Trading at 22.86% from the 50-Day Moving Average
After a stumble in the market that brought INBX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.21% of loss for the given period.
Volatility was left at 5.85%, however, over the last 30 days, the volatility rate increased by 5.54%, as shares surge +25.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.57% upper at present.
During the last 5 trading sessions, INBX rose by +10.41%, which changed the moving average for the period of 200-days by -0.49% in comparison to the 20-day moving average, which settled at $14.70. In addition, Inhibrx Biosciences Inc saw 18.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INBX starting from Kayyem Jon Faiz, who purchase 69,686 shares at the price of $14.23 back on Nov 19 ’24. After this action, Kayyem Jon Faiz now owns 51,093 shares of Inhibrx Biosciences Inc, valued at $991,416 using the latest closing price.
Kayyem Jon Faiz, the Director of Inhibrx Biosciences Inc, purchase 37,500 shares at $14.19 during a trade that took place back on Nov 20 ’24, which means that Kayyem Jon Faiz is holding 69,843 shares at $532,204 based on the most recent closing price.
Stock Fundamentals for INBX
Current profitability levels for the company are sitting at:
- -1502.62% for the present operating margin
- -4.82% for the gross margin
The net margin for Inhibrx Biosciences Inc stands at 8614.85%. The total capital return value is set at -1.51%. Equity return is now at value 3250.55%, with 648.69% for asset returns.
Based on Inhibrx Biosciences Inc (INBX), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -21.23. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -112.47.
Currently, EBITDA for the company is 1.7 billion with net debt to EBITDA at -0.12. When we switch over and look at the enterprise to sales, we see a ratio of 138.74. The receivables turnover for the company is 0.93for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.12.
Conclusion
In conclusion, Inhibrx Biosciences Inc (INBX) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
